News    Sports    Entertainment Log In    My Page    Help   
360° SearchNetworkHot SpotsTrends
 
Advanced Search Options >>
Monday, March 22, 2010 1:45 AM

Chris Schott

Image
Type: Person
Name: Chris Schott
First Reported Mar 18 2010 - Updated Mar 19 2010 - 4 Documents
Teva Pharmaceutical Industries LTD
Teva Pharmaceutical Industries LTD

Teva Takes Over

Teva Pharmaceutical Industries popped another generic pill maker into its portfolio Thursday, the latest acquisition on the its road to becoming one of the world's largest drugmakers.On Thursday, the Israel-based company announced that it entered a definitive ... [Published Mar 18 2010 by Forbes.com via MSN Money]
First Reported Mar 03 2010 - Updated Mar 03 2010 - 1 Documents

Bristol?s Accidental Revolutionary

James Cornelius became chief executive of Bristol-Myers Squibb reluctantly, as a result of a scandal that plagued his predecessor. He wound up leading the whole drug industry in a new, leaner direction, focused on rarer diseases and employing fewer p ... [Published Mar 03 2010 by Forbes.com]
First Reported Dec 14 2009 - Updated Dec 14 2009 - 1 Documents
Pfizer Inc
Pfizer Inc

The Start of a Comeback for Pfizer’s Dividend?

Pfizer is raising its dividend , and the company plans to keep hiking payouts to shareholders in years to come (”barring significant unforeseen events,” of course). Still, even barring those unforeseen events, it could be a while before the company ... [Published Dec 14 2009 by WSJ.com: Health Blog]
First Reported Dec 11 2009 - Updated Dec 11 2009 - 1 Documents

Eli Lilly Isn’t Planning to Buy Its Way Around the Patent Cliff

Eli Lilly knows a thing or two about the patent cliff: Between now and 2013, patent protection will expire on drugs that account for more than half of its current revenue, this morning’s WSJ notes . Plenty of big pharma players face this kind of problem, ... [Published Dec 11 2009 by WSJ.com: Health Blog]
First Reported Dec 10 2009 - Updated Dec 10 2009 - 1 Documents
Eli Lilly & Company
Eli Lilly & Company

Behind the Headlines: Eli Lilly & Co., Oxford Industries Inc., and Shutterfly Inc.

Pipeline concerns plague a drug giant, while a clothier's shares see a cup-and-handle formationby Joseph Hargett (jhargett@sir-inc.com) 12/10/2009 2:00 PMText Size| Email a friend | Print | ShareKeywords:LLYShares of Eli Lilly & Co. (LLY: sentiment, ... [Published Dec 10 2009 by Schaeffers Research]

Quotes

...for meaningful synergies [and] accretion, we view today's announcement as a clear positive for Teva," says JPMorgan Chase analyst Chris Schott. "the deal will strengthen the company's position in germany (which despite its challenges remains the second largest generic market in the world) as well as other european markets with significant growth potential."
Teva Takes Over [Forbes.com via MSN Money - Mar 18 2010]

More Content

All (18) | News (16) | Reports (0) | Blogs (2) | Audio/Video (0) | Fact Sheets (0)
sort by: Date | Relevance
Teva Takes Over [Forbes.com via MSN Money - Mar 18 2010]
Generic deals may still hold appeal for Pfizer [FinanzNachrichten.de - Mar 18 2010]
UPDATE 4-Teva to buy Ratiopharm for nearly $5 bln [Interactive Investor - Mar 18 2010]
UPDATE 3-Teva to buy Ratiopharm for over $4.8 b... [Reuters - Mar 18 2010]
UPDATE 3-Teva to buy Ratiopharm for over $4.8 b... [FinanzNachrichten.de - Mar 18 2010]
DEALTALK-Pfizer may target Stada if it loses Ra... [Reuters UK - Mar 17 2010]
Bristol?s Accidental Revolutionary [Forbes.com - Mar 03 2010]
Israeli Stocks to Watch [Minyanville - Feb 25 2010]
Watson Pharmaceuticals, Inc. Q4 2009 Earnings C... [Seeking Alpha - Feb 23 2010]
Merck & Co., Inc. Q4 2009 Earnings Call Tra... [Seeking Alpha - Feb 16 2010]
Teva Q4 profit rises, maintains 2010 outlook [Yahoo! Malaysia - Feb 16 2010]
UPDATE 3-Merck revenue beats, confident on fina... [Reuters UK - Feb 16 2010]
UPDATE: Teva Swings To 4Q Profit; Sales Driven ... [Nasdaq - Feb 16 2010]
UPDATE 3-Teva Q4 profit rises, maintains 2010 o... [FinanzNachrichten.de - Feb 16 2010]
Cephalon, Inc. Q4 2009 Earnings Call Transcript [Seeking Alpha - Feb 12 2010]
Behind the Headlines: Eli Lilly & Co., Oxfo... [Schaeffers Research - Dec 10 2009]
1
In Focus
  •  
James Cornelius, Adolf Merckle, Ludwig Merckle, [more]
  •  
Teva Pharmaceutical Industries LTD, Ratiopharm, Pfizer Inc, [more]
  •  
The Iraqi Resistance Islamic Front, Food and Drug Administration, European Union, [more]
  •  
Dividend, Patent, Acquisition, [more]
  •  
SITAGLIPTIN, Abilify, Erbitux, [more]
  •  
Bristol, Frankfurt am Main, Phoenix (Arizona, United States), [more]
  •  
Israel, Germany, United States, [more]
  •  
Medication, Mergers & Acquisitions, Financial Reporting, [more]
  •  
Pharma & Biotech, Banking & Financial Services, Health
WSJ.com: Health Blog, FinanzNachrichten.de, Forbes.com, [more]
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
The Start of a Comeback for Pfizer’s Dividend? [WSJ.com: Health Blog - Dec 14 2009]
Pfizer is raising its dividend, and the company plans to keep hiking payouts to shareholders in years to come (”barring significant unforeseen events,” of course). ...
Eli Lilly Isn’t Planning to Buy Its Way Around ... [WSJ.com: Health Blog - Dec 11 2009]
Eli Lilly knows a thing or two about the patent cliff: Between now and 2013, patent protection will expire on drugs that account for more than half of its current ...
1
Products & Services
Silobreaker.com
Enterprise Online Service
Enterprise Software Suite
Widgets & API
How To Use
Silobreaker
RSS
API
Widgets
Advertise With Us
Advertise
Follow Us
Press Room
Blog
YouTube
Twitter
About Us
About Silobreaker
Background and History
Why Silobreaker?
Value Proposition
Technology
Team
Contact Us
Legal
Terms of Use
Privacy Policy


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2009 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.